Table 4.

COVID-19 and HEART: HIGHLIGHTS.

SARS-COv-2 may entry in myocardiocytes causing myocardial injury

Cardiac damage biomarkers may identify COVID-19 patients at increased risk of worse clinical condition or death.

Hypertension, diabetes, and coronary artery disease are the most prevalent comorbidities among COVID-19 patients.

COVID-19 patients with underlying cardiovascular diseases are more likely to develop severe degree of the disease and death.

Fulminant myocarditis is a rare event and appears early in the clinical history of COVID-19 patients.

Arrhythmias represent a not rare clinical presentation of COVID-19 and might complicate the clinical course of disease and worse the prognosis.

The usual cardiovascular therapy, including the anti-hypertensive drugs, should be continued during the SARS-COV-2 pandemic.

There is no scientific evidence to suggest that treatment with ACE-I or ARBs should be discontinued because of the SARS-CoV-2 infection or COVID-19.

All physicians involved in COVID-19 management should be aware of cardiovascular implications of the disease

A cardiologist with high experience in intensive care medicine should be part of COVID-19 care team.